Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28087461 | 0.82 | ESR1 (0.43) | ESR1ELANESMN1; SMN2 | |
| SCHEMBL14965029 | 0.78 | KDM4E (0.51) | LMNAKDM4ETP53SMN1; SMN2HTR2C | |
| SCHEMBL16293189 | 0.75 | HPGD (0.38) | ESR1LMNAHTTRECQLKDM4E | |
| SCHEMBL16293188 | 0.74 | POLB (0.39) | ESR1LMNAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL16293796 | 0.74 | KDM4E (0.44) | LMNAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL11202279 | 0.66 | ESR1 (0.49) | ESR1ELANEHTTSMN1; SMN2 | |
| SCHEMBL4556149 | 0.65 | SMN1; SMN2 (0.43) | ESR1LMNAKDM4ESMN1; SMN2HTR2C | |
| SCHEMBL11200448 | 0.64 | ESR1 (0.60) | ESR1ELANE | |
| SCHEMBL27978693 | 0.64 | MEN1 (0.45) | LMNASMN1; SMN2 | |
| SCHEMBL14969468 | 0.63 | STAT3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104011054-B | As the thieno of potassium channel inhibitors and Furanopyrimidines class and pyridines | 森申有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | ESR1 2964/4885ELANE 4652/4885LMNA 3153/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | ESR1 3009/4885ELANE 4670/4885LMNA 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.